Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin

By Foster Graham   Fried Michael   Hadziyannis Stephanos   Messinger Diethelm   Freivogel Klaus   Weiland Ola  

Scandinavian Journal of Gastroenterology, Vol. 42, Iss. 2, 2007-01 ,pp. : 247-255

Informa Healthcare

Access to resources Recommend Favorite

Peginterferon α-2a Combination Therapies in Chronic Hepatitis C Patients Who Relapsed After or Had a Viral Breakthrough on Therapy with Standard Interferon α-2b Plus Ribavirin: A Pilot Study of Efficacy and Safety

By Herrine Steven   Brown Robert   Bernstein David   Ondovik Michael   Lentz Ellen   Te Helen  

Digestive Diseases and Sciences, Vol. 50, Iss. 4, 2005-04 ,pp. : 719-726

Springer Publishing Company

Access to resources Recommend Favorite

Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study

By Nishiguchi Shuhei   Enomoto Hirayuki   Aizawa Nobuhiro   Nishikawa Hiroki   Osaki Yukio   Tsuda Yasuhiro   Higuchi Kazuhide   Okazaki Kazuichi   Seki Toshihito   Kim Soo   Hongo Yasushi   Jyomura Hisato   Nishida Naoshi   Kudo Masatoshi  

Journal of Gastroenterology, Vol. 49, Iss. 3, 2014-03 ,pp. : 492-501

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy and Safety of Sofosbuvir Plus Ribavirin Treatment for Patients with Chronic Hepatitis C Genotype 2

By  

Digestive Diseases, Vol. 34, Iss. 6, 2016-10 ,pp. : 627-631

Karger

Access to resources Recommend Favorite

Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse

By Lagging Martin  

Scandinavian Journal of Gastroenterology, Vol. 48, Iss. 7, 2013-07 ,pp. : 839-847

Informa Healthcare

Access to resources Recommend Favorite